Skip to main content
    V

    Vera Therapeutics Inc (VERA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $26.97
    -1.13 (-4.02%)

    Market Cap: $2.03B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Vera Therapeutics Inc (VERA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Vera Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$299.62M, operating cash flow was -$241.10M and free cash flow was -$241.73M. The quarter ended Sep 30, 2026 had revenue of $10.28M and net income of -$93.71M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $315.47M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Cost of revenue$0$0$0$0$0$0$509.00K
    Gross profit$0$0$0$0$0$0-$509.00K
    Research and development$215.26M$126.17M$78.22M$68.99M$22.48M$45.21M$7.29M
    Operating income-$315.47M-$167.17M-$102.01M-$90.90M-$34.40M-$52.24M-$11.96M
    Net income-$299.62M-$152.15M-$95.99M-$89.06M-$32.61M-$53.41M-$11.85M
    EBITDAN/AN/AN/A-$90.66M-$32.43MN/A-$11.29M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$10.28M$0$0$0$0$0$0$0$0$0$0$0
    Gross profit$6.98M$0$0$1.13M$0$0$0N/A$0$0$0$635.00K
    Operating income-$95.70M-$112.49M-$125.13M-$94.21M-$83.93M-$80.14M-$57.19M-$48.91M-$49.80M-$37.34M-$31.11M-$27.03M
    Net income-$93.71M-$109.47M-$121.03M-$91.10M-$80.29M-$76.53M-$51.69M-$43.42M-$46.63M-$33.71M-$28.38M-$25.66M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $75.39M by $279.34M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$734.73M$655.68M$175.55M$131.44M$83.75M$54.55M$5.38M
    Current assets$728.88M$651.22M$172.02M$125.70M$82.54M$54.26M$3.56M
    Cash and equivalents$354.73M$92.65M$45.68M$43.46M$79.67M$53.65M$3.19M
    Total liabilities$130.21M$78.53M$73.86M$54.53M$14.16M$4.33M$41.93M
    Short-term debt$549.00K$1.48M$2.44M$2.65MN/A$2.00K$122.00K
    Long-term debt$74.84M$50.69M$49.88M$24.81M$4.92MN/AN/A
    Shareholder equity$604.52M$577.15M$101.69M$76.91M$69.59M-$89.35M-$36.55M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$465.75M$532.98M$621.74M$734.73M$517.50M$578.53M$610.17M$655.68M$368.56M$397.29M$419.36M$175.55M
    Total liabilities$132.57M$125.23M$122.04M$130.21M$118.62M$110.25M$75.17M$78.53M$79.50M$69.42M$65.81M$73.86M
    Cash and equivalents$55.32M$48.88M$114.35M$354.73M$57.77M$49.12M$55.09M$92.65M$27.26M$25.09M$69.11M$45.68M
    Shareholder equity$333.19M$407.76M$499.70M$604.52M$398.88M$468.28M$535.00M$577.15M$289.06M$327.87M$353.54M$101.69M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$241.10M-$134.68M-$92.18M-$67.60M-$23.71M-$34.81M-$10.29M
    Capital expenditures$630.00K$972.00K$63.00K$62.00K$5.00M$99.00K$125.00K
    Free cash flow-$241.73M-$135.65M-$92.24M-$67.66M-$28.71M-$34.91M-$10.41M
    Share repurchases$0$13.00K$0N/A$2.77M$0N/A
    Investing cash flow$194.29M-$425.03M-$39.43M-$70.55M-$4.20M-$42.00K-$125.00K
    Financing cash flow$308.90M$606.67M$133.54M$101.93M$53.88M$85.29M-$137.00K
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$99.18M-$100.25M-$106.50M-$69.99M-$61.91M-$54.80M-$54.41M-$39.18M-$36.88M-$24.78M-$33.83M-$25.14M
    Capital expendituresN/AN/A$23.00K$102.00K$133.00K$208.00K$187.00K$645.00K$238.00K$89.00K$0$63.00K
    Free cash flowN/AN/A-$106.52M-$70.10M-$62.04M-$55.01M-$54.59M-$39.83M-$37.12M-$24.87M-$33.83M-$25.21M
    Last 12 quarters

    Frequently Asked Questions About VERA

    What is Vera Therapeutics' annual revenue?

    Vera Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Vera Therapeutics profitable?

    No. Vera Therapeutics reported net income of -$299.62M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does VERA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$241.10M minus capital expenditures of $630.00K produced free cash flow of -$241.73M.

    How much debt does Vera Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $74.84M, short-term debt of $549.00K and cash and equivalents of $354.73M.